Roche Genentech Innovation Center Boston opens in Allston
- The centre will serve as Roche and Genentech’s Cardiovascular, Renal and Metabolism (CVRM) hub at Harvard’s Enterprise Research Campus in Allston.
- Roche and Genentech signed a 10-year lease for a 95,000 sq. metre facility with capacity for up to 500 people across research, clinical development and data science.
- The site brings together discovery research, clinical development, AI and data science to create an end-to-end R&D environment from early discovery through late-stage clinical development.
- The centre is part of Roche and Genentech’s USD 50 billion US investment in manufacturing and R&D, complementing recent investments in Holly Springs (NC) and Hillsboro (OR).
Purpose and focus
The Roche Genentech Innovation Center Boston will act as the group’s Cardiovascular, Renal and Metabolism (CVRM) hub, bringing together scientists across discovery research, clinical development, artificial intelligence and data science to drive drug discovery and development.
Location and footprint
Located at Harvard’s Enterprise Research Campus in Allston, the centre occupies a 95,000 square metre site under a 10-year lease and has capacity for up to 500 employees across research, clinical development, data science and other areas.
Capabilities and organisation
The centre is designed as an end-to-end R&D environment spanning early-stage discovery through late-stage clinical development and explicitly integrates AI and data science specialists to support innovation in drug discovery and clinical analysis.
Strategic context
The investment expands Roche and Genentech’s presence in Greater Boston and forms part of a broader USD 50 billion commitment to US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina and Hillsboro, Oregon. Harvard’s Enterprise Research Campus—adjacent to Harvard’s Science and Engineering Complex and near Harvard Business School—aims to complete its first phase of construction in 2026.
Source: Roche
